Publicaciones (28) Publicaciones de CARLOS MANUEL GONZÁLEZ FERNÁNDEZ

2023

  1. Salivary gland ultrasound in clinical practice: What is its real usefulness?

    Reumatologia Clinica, Vol. 19, Núm. 5, pp. 260-265

2022

  1. Long-Term Retention Rate of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting

    Journal of Clinical Rheumatology, Vol. 28, Núm. 1, pp. E150-E155

2021

  1. Clinical impact of nailfold capillaroscopy in daily clinical practice

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 258-262

  2. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review

    Advances in Therapy, Vol. 38, Núm. 2, pp. 868-884

2020

  1. Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 333-338

  2. Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study

    Arthritis Care and Research, Vol. 72, Núm. 6, pp. 822-828

2019

  1. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences

    Arthritis Research and Therapy, Vol. 21, Núm. 1

2018

  1. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients

    Clinical and Experimental Rheumatology, Vol. 36, Núm. 1, pp. 88-93

  2. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

    The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224

  3. Salivary gland ultrasound is linked to the autoimmunity profile in patients with primary Sjögren’s syndrome

    Journal of International Medical Research, Vol. 48, Núm. 1

2017

  1. Planes de autoprotección y de emergencias

    Reus

2016

  1. Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients?

    Rheumatology International, Vol. 36, Núm. 6, pp. 793-797

2011

  1. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

    Reumatologia Clinica, Vol. 7, Núm. 5, pp. 284-298

  2. Enfermedad pulmonar intersticial rápidamente progresiva y fatal en una paciente con síndrome de superposición de lupus eritematoso sistémico y esclerosis sistémica

    Reumatologia Clinica, Vol. 7, Núm. 1, pp. 13-19

2009

  1. Relationship between spinal mobility and disease activity, function, quality of life and radiology. A cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER)

    Clinical and Experimental Rheumatology, Vol. 27, Núm. 3, pp. 439-445

2007

  1. Estudio 3e

    Reumatologia Clinica Suplementos, Vol. 3, Núm. SUPPL. 2, pp. 43-45

  2. Estudio 3e

    Reumatologia Clinica

  3. Monografía SER: Artritis infecciosa.

    Editorial Médica Panamericana S.A.

2005

  1. Tratamiento biológico de las enfermedades reumáticas

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 9, Núm. 28, pp. 1830-1839

2003

  1. Infliximab in refractory spondyloarthropathies: A multicentre 38 week open study

    Annals of the Rheumatic Diseases, Vol. 62, Núm. 12, pp. 1239-1240